Skip to main content
Biosimilars
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
Read More
Biosimilars
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
Read More
Biosimilars
Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
Read More
Biosimilars
Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell NHL
Read More
Biosimilars
Scaled Integration of FDA-Approved Biosimilars
Read More
Biosimilars
Biosimilar Uptake of Filgrastim and Impact on Spending in Medicare Part D from 2015 to 2019
Read More
Biosimilars
Evaluation of Real-World Cost-Savings and Utilization of Biosimilar Drugs in a Community-Based Oncology Practice
Read More
Biosimilars
Utilization and Clinical Characteristics for the Trastuzumab Originator, Biosimilars, and Other HER2 Inhibitors
Read More
Biosimilars
Cost-Savings from Conversion to Biosimilar Pegfilgrastim-cbqv Allowed Budget-Neutral Expanded Access to Antineoplastic Therapy
Read More
Biosimilars
2021 in Review
Read More
Page 72 of 199
Results 711 - 720 of 1986